ATE449856T1 - Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten - Google Patents

Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten

Info

Publication number
ATE449856T1
ATE449856T1 AT98965434T AT98965434T ATE449856T1 AT E449856 T1 ATE449856 T1 AT E449856T1 AT 98965434 T AT98965434 T AT 98965434T AT 98965434 T AT98965434 T AT 98965434T AT E449856 T1 ATE449856 T1 AT E449856T1
Authority
AT
Austria
Prior art keywords
humanized monoclonal
monoclonal antibodies
present
induced diseases
shigatoxin
Prior art date
Application number
AT98965434T
Other languages
German (de)
English (en)
Inventor
Jeffrey R Stinson
Hing Wong
Alison D O'brien
Clare K Schmitt
Angela Melton-Celsa
Original Assignee
Sunol Molecular Corp
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunol Molecular Corp, Jackson H M Found Military Med filed Critical Sunol Molecular Corp
Application granted granted Critical
Publication of ATE449856T1 publication Critical patent/ATE449856T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98965434T 1997-12-23 1998-12-22 Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten ATE449856T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6863597P 1997-12-23 1997-12-23
US09/215,163 US20030170248A1 (en) 1997-12-23 1998-12-18 Humanized monoclonal antibodies that protect against shiga toxin induced disease
PCT/US1998/027267 WO1999032645A1 (en) 1997-12-23 1998-12-22 Humanized monoclonal antibodies that protect against shiga toxin induced disease

Publications (1)

Publication Number Publication Date
ATE449856T1 true ATE449856T1 (de) 2009-12-15

Family

ID=26749187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98965434T ATE449856T1 (de) 1997-12-23 1998-12-22 Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten

Country Status (11)

Country Link
US (6) US20030170248A1 (https=)
EP (1) EP1042492B1 (https=)
JP (1) JP4450505B2 (https=)
AT (1) ATE449856T1 (https=)
AU (1) AU764091B2 (https=)
CA (1) CA2316411C (https=)
DE (1) DE69841331D1 (https=)
DK (1) DK1042492T3 (https=)
ES (1) ES2339618T3 (https=)
PT (1) PT1042492E (https=)
WO (1) WO1999032645A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
ES2270598T3 (es) * 1998-05-20 2007-04-01 Teijin Limited Anticuerpos humanizados que reconocen la verotoxina ii y linea celular que produce los mismos.
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CA2439402A1 (en) * 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CN100441689C (zh) * 2006-01-20 2008-12-10 中国人民解放军第三军医大学 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
US8293245B2 (en) * 2006-04-20 2012-10-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
EP2545936A3 (en) * 2006-05-31 2013-02-20 Thallion Pharmaceuticals Inc. Methods, compositions, and kits for treating Shiga toxin associated conditions
EP2172481B1 (en) * 2008-10-06 2014-10-29 Novoplant GmbH Proteolytically stable antibody formats
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) * 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5747272A (en) * 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) * 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
US7910096B2 (en) * 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
US7807184B2 (en) * 2003-07-21 2010-10-05 Interuet International B.V. Hybrid Shiga-like toxin
US20050226883A1 (en) * 2004-02-06 2005-10-13 Paul Averback Humanized antibody
ES2532985T3 (es) * 2006-02-16 2015-04-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Proteínas quiméricas de toxoide de Shiga
US8293245B2 (en) * 2006-04-20 2012-10-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions

Also Published As

Publication number Publication date
US20100166753A1 (en) 2010-07-01
JP2003521219A (ja) 2003-07-15
AU764091B2 (en) 2003-08-07
JP4450505B2 (ja) 2010-04-14
AU2090299A (en) 1999-07-12
EP1042492A1 (en) 2000-10-11
US20140135481A1 (en) 2014-05-15
CA2316411C (en) 2009-02-17
DE69841331D1 (de) 2010-01-07
US20100189715A1 (en) 2010-07-29
US20030170248A1 (en) 2003-09-11
US20070003560A1 (en) 2007-01-04
CA2316411A1 (en) 1999-07-01
US20070160607A1 (en) 2007-07-12
ES2339618T3 (es) 2010-05-21
PT1042492E (pt) 2010-01-08
EP1042492B1 (en) 2009-11-25
WO1999032645A1 (en) 1999-07-01
DK1042492T3 (da) 2010-01-18

Similar Documents

Publication Publication Date Title
ATE421883T1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
ATE449856T1 (de) Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten
BR0011838A (pt) Elementos misturadores estáticos empilhados
DE69128543D1 (de) Monoklonale antikörper der maus
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE305971T1 (de) Monoklonale antikörper und fv gegen das cd2 antigen
DE69942671D1 (de) Humanisierte antikoerper gegen gamma-interferon
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
DE59508864D1 (de) MONOKLONALER ANTIKÖRPER GEGEN CD44v6
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
DE69433406D1 (de) Antikörper gegen cd40
NZ593428A (en) Therapeutic human anti-il-1r1 monoclonal antibody
FI943635L (fi) Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten vasta-aineiden suunnittelu, kloonaus ja ekspressio
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
SI1684770T1 (sl) Oligo-beta-(1,3)-glukan in monoklonska protitelesa proti raku
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
BR9803296A (pt) Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma.
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
ATE411056T1 (de) Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
EP0554670A3 (en) Specific antibodies against activated platelets, their production and applications in diagnostics and therapeutics

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1042492

Country of ref document: EP